Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin/Lucentis) Compared With Intraocular Triamcinolone (Volon A) in Patients With Clinical Significant Diabetic Macular Edema

Trial Profile

A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin/Lucentis) Compared With Intraocular Triamcinolone (Volon A) in Patients With Clinical Significant Diabetic Macular Edema

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary) ; Triamcinolone
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms TRIASTIN
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Jan 2018 Results (n=25) of post hoc analysis of morphologic characteristics in OCT, FA and CF images assessing the effect of ranibizumab vs triamcinolone on changes in retinal morphology published in the Graefes Archive for Clinical and Experimental Ophthalmology
    • 03 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top